Payment overview · 2025
General Payments
$782.83
18 reported records · 7 companies
Healthcare provider profile · identity verified
Ebrahim Sadighim, MD
Allopathic & Osteopathic Physicians|Internal Medicine · GREAT NECK, NY · NPI 1215021530
Verified facts
What the public records show
CMS Open Payments records show Ebrahim Sadighim, MD received $782.83 in general payments during 2025 across 18 reported records.
Amgen Inc. accounted for 43.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 10 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Creon, Gemtesa, Jardiance, Linzess, Mounjaro, Zenpep.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CREON as an associated drug or biological on 91561 records involving 20616 distinct recipient NPIs. Public Medicare Part D data also shows 27 claims for Creon by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 69 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 44 claims for Synthroid by this doctor in 2024.
Aimmune Therapeutics, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ZENPEP as an associated drug or biological on 32144 records involving 12432 distinct recipient NPIs. Public Medicare Part D data also shows 36 claims for Zenpep by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 38 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Trulicity by this doctor in 2024.
Sumitomo Pharma America, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported GEMTESA as an associated drug or biological on 61692 records involving 22152 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Gemtesa by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Amgen Inc. | Unresolved — no canonical attribution shown | $340.80 | 43.5% | 5 | 2025 |
| Kowa Pharmaceuticals America, Inc. | Unresolved — no canonical attribution shown | $132.98 | 17.0% | 4 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $120.62 | 15.4% | 1 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $83.58 | 10.7% | 3 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $41.94 | 5.4% | 3 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $34.22 | 4.4% | 1 | 2025 |
| Aimmune Therapeutics, Inc. | Unresolved — no canonical attribution shown | $28.69 | 3.7% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $782.83 | 18 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $340.80 | 5 | 2025 |
Source payment records
|
|||||
| ZORYVE Normalized: zoryve |
Drug | Kowa Pharmaceuticals America, Inc. | $132.98 | 4 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $120.62 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $84.37 | 3 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $83.58 | 3 | 2025 |
Source payment records
|
|||||
| CREON Normalized: creon |
Drug | ABBVIE INC. | $41.94 | 3 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $34.22 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $34.22 | 1 | 2025 |
Source payment records
|
|||||
| ZENPEP Normalized: zenpep |
Drug | Aimmune Therapeutics, Inc. | $28.69 | 1 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $28.44 | 2 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| CREON creon |
2025 | Creon | 2024 | 27 | exact normalized | Medicare Part D |
| GEMTESA gemtesa |
2025 | Gemtesa | 2024 | 17 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 24 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| LINZESS linzess |
2025 | Linzess | 2024 | 69 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 38 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| ZENPEP zenpep |
2025 | Zenpep | 2024 | 36 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | CREON open payments reported associated product |
CMS Open Payments — General Payments 91561 supporting records · 20616 recipient NPIs · example record 1201352608 |
Creon · 2024 Exact normalized brand match · 1 Part D row |
27 | 13 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
69 | 20 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
44 | 11 |
| Aimmune Therapeutics, Inc. Exact reporting entity; no affiliate inference |
2025 | ZENPEP open payments reported associated product |
CMS Open Payments — General Payments 32144 supporting records · 12432 recipient NPIs · example record 1249641927 |
Zenpep · 2024 Exact normalized brand match · 1 Part D row |
36 | 14 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
24 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
24 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
38 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| Sumitomo Pharma America, Inc. Exact reporting entity; no affiliate inference |
2025 | GEMTESA open payments reported associated product |
CMS Open Payments — General Payments 61692 supporting records · 22152 recipient NPIs · example record 1176593503 |
Gemtesa · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Rosuvastatin Calcium | Rosuvastatin Calcium | 288 | 85 |
| Atorvastatin Calcium | Atorvastatin Calcium | 282 | 81 |
| Metoprolol Succinate | Metoprolol Succinate | 192 | 53 |
| Amlodipine Besylate | Amlodipine Besylate | 183 | 60 |
| Levothyroxine Sodium | Levothyroxine Sodium | 181 | 48 |
| Losartan Potassium | Losartan Potassium | 179 | 54 |
| Omeprazole | Omeprazole | 163 | 65 |
| Diclofenac Sodium | Diclofenac Sodium | 151 | 50 |
| Hydrochlorothiazide | Hydrochlorothiazide | 124 | 39 |
| Metformin Hcl Er | Metformin Hcl | 115 | 38 |
| Ozempic | Semaglutide | 115 | 21 |
| Tamsulosin Hcl | Tamsulosin Hcl | 112 | 40 |
| Vascepa | Icosapent Ethyl | 109 | 33 |
| Zolpidem Tartrate | Zolpidem Tartrate | 104 | 22 |
| Gabapentin | Gabapentin | 101 | 38 |
| Escitalopram Oxalate | Escitalopram Oxalate | 96 | 26 |
| Famotidine | Famotidine | 93 | 37 |
| Meloxicam | Meloxicam | 85 | 52 |
| Azithromycin | Azithromycin | 76 | 58 |
| Enalapril Maleate | Enalapril Maleate | 76 | 21 |
| Fluticasone Propionate | Fluticasone Propionate | 73 | 33 |
| Ketoconazole | Ketoconazole | 70 | 33 |
| Alprazolam | Alprazolam | 69 | 29 |
| Linzess | Linaclotide | 69 | 20 |
| Trazodone Hcl | Trazodone Hcl | 69 | 21 |
| Eliquis | Apixaban | 67 | 20 |
| Januvia | Sitagliptin Phosphate | 67 | 17 |
| Furosemide | Furosemide | 66 | 25 |
| Glipizide Er | Glipizide | 66 | 16 |
| Memantine Hcl | Memantine Hcl | 60 | 14 |
| Pantoprazole Sodium | Pantoprazole Sodium | 60 | 19 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 59 | 19 |
| Hydrocortisone | Hydrocortisone | 59 | 36 |
| Metformin Hcl | Metformin Hcl | 57 | 19 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 56 | 26 |
| Montelukast Sodium | Montelukast Sodium | 54 | 14 |
| Simvastatin | Simvastatin | 52 | 17 |
| Valsartan | Valsartan | 52 | 13 |
| Atenolol | Atenolol | 51 | 16 |
| Finasteride | Finasteride | 48 | 17 |
| Icosapent Ethyl | Icosapent Ethyl | 47 | 17 |
| Allopurinol | Allopurinol | 45 | 13 |
| Synthroid | Levothyroxine Sodium | 44 | 11 |
| Xarelto | Rivaroxaban | 41 | suppressed |
| Clonazepam | Clonazepam | 40 | suppressed |
| Prednisone | Prednisone | 40 | 27 |
| Ezetimibe | Ezetimibe | 38 | 14 |
| Metoprolol Tartrate | Metoprolol Tartrate | 38 | suppressed |
| Mounjaro | Tirzepatide | 38 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 37 | 30 |
| Zenpep | Lipase/Protease/Amylase | 36 | 14 |
| Ibuprofen | Ibuprofen | 34 | 23 |
| Ventolin Hfa | Albuterol Sulfate | 34 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 33 | suppressed |
| Potassium Chloride | Potassium Chloride | 33 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 32 | suppressed |
| Myrbetriq | Mirabegron | 31 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 30 | suppressed |
| Repatha Sureclick | Evolocumab | 29 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 28 | suppressed |
| Creon | Lipase/Protease/Amylase | 27 | 13 |
| Duloxetine Hcl | Duloxetine Hcl | 27 | suppressed |
| Lisinopril | Lisinopril | 27 | suppressed |
| Mupirocin | Mupirocin | 27 | 21 |
| Amoxicillin | Amoxicillin | 25 | 20 |
| Lovastatin | Lovastatin | 25 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 25 | 13 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 25 | 18 |
| Citalopram Hbr | Citalopram Hydrobromide | 24 | suppressed |
| Colchicine | Colchicine | 24 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 24 | 11 |
| Jardiance | Empagliflozin | 24 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 24 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 24 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 22 | suppressed |
| Cephalexin | Cephalexin | 22 | 19 |
| Propranolol Hcl | Propranolol Hcl | 21 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 21 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 20 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 20 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 20 | suppressed |
| Aripiprazole | Aripiprazole | 19 | suppressed |
| Carvedilol | Carvedilol | 19 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 19 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 18 | suppressed |
| Betamethasone Dipropionate | Betamethasone Dipropionate | 18 | 11 |
| Breyna | Budesonide/Formoterol Fumarate | 18 | suppressed |
| Celecoxib | Celecoxib | 18 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 18 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 18 | suppressed |
| Gemtesa | Vibegron | 17 | suppressed |
| Primidone | Primidone | 17 | suppressed |
| Ammonium Lactate | Ammonium Lactate | 16 | 13 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 16 | 12 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 16 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 16 | suppressed |
| Advair Diskus | Fluticasone Propion/Salmeterol | 15 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 15 | suppressed |
| Nifedipine Er | Nifedipine | 15 | suppressed |
| Spironolactone | Spironolactone | 15 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 14 | suppressed |
| Lorazepam | Lorazepam | 14 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 14 | 11 |
| Pregabalin | Pregabalin | 14 | suppressed |
| Ciclopirox | Ciclopirox | 13 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 13 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 13 | suppressed |
| Loperamide | Loperamide Hcl | 13 | suppressed |
| Mirtazapine | Mirtazapine | 13 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 13 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 13 | 13 |
| Tiadylt Er | Diltiazem Hcl | 13 | suppressed |
| Trulicity | Dulaglutide | 13 | suppressed |
| Fluocinonide | Fluocinonide | 12 | suppressed |
| Glimepiride | Glimepiride | 12 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 12 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 12 | suppressed |
| Praluent Pen | Alirocumab | 12 | suppressed |
| Torsemide | Torsemide | 12 | suppressed |
| Dutasteride | Dutasteride | 11 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 11 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 11 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 11 | suppressed |
| Methocarbamol | Methocarbamol | 11 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 11 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 11 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $782.83 · 18 records | Amgen Inc. | CREON, GEMTESA, JARDIANCE, LINZESS, MOUNJARO, OTEZLA, REPATHA, ZENPEP, ZEPBOUND, ZORYVE | 9 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Creon play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error